Fig. 4From: SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesotheliomaMLN4924 in combination with cisplatin effectively restored immunogenic cell death in resistant mesothelioma cells. Primary MPM cells derived from 3 different histopathological subtypes, epithelioid (EPI BAP1+ UPN7 and EPI BAP1- UPN11), biphasic (BIP BAP1+ UPN14 and BIP BAP1- UPN16) and sarcomatous (SAR BAP1+ UPN22 and SAR BAP- UPN23) were incubated in fresh medium (CTRL), with 50 μM cisplatin (PT), 0.2 μM MLN4924 (MLN) or their combination (PT+MLN) for 24 h Panels A-B) or 48 h (panel C). A. Calreticulin (CRT) exposure on the plasma membrane was measured by flow cytometry in duplicates. Data are expressed as means of 2 primary MPM for each histopathological subtype used + SD (n = 3). ***p < 0.001: treated cells vs CTRL cells; °p < 0.05, °°°p < 0.001: PT+MLN-treated cells vs PT-treated cells. B. ATP release was measured by a chemiluminescence-based assay in duplicates. Data are expressed as means of 2 primary MPM for each histopathological subtype used + SD (n = 3). ***p < 0.001: treated cells vs CTRL cells; °°°p < 0.001: PT+MLN-treated cells vs PT-treated cells. C. HMGB1 release was measured by ELISA in duplicates. Data are expressed as means of 2 primary MPM for each histopathological subtype used + SD (n = 3). **p < 0.01, ***p < 0.001: treated cells vs CTRL cells; °°p < 0.01: PT+MLN-treated cells vs PT-treated cells. D. Phagocytosis by dendritic cells was measured by flow cytometry in duplicates. Data are expressed as means of 2 primary MPM for each histopathological subtype used + SD (n = 3). *p < 0.05, ***p < 0.001: treated cells vs CTRL cells; °p < 0.05, °°°p < 0.001: PT+MLN-treated cells vs PT-treated cells. E. CD8+CD107a+ lymphocytes, collected after co-culture with dendritic cells that have phagocytized MPM cells, were quantified by flow cytometry, in duplicates. Data are expressed as means of 2 primary MPM for each histopathological subtype used+ SD (n = 3). ***p < 0.001: treated cells vs CTRL cells; °°°p < 0.01: PT+MLN-treated cells vs PT-treated cells. F-G. AB1 tumors were subcutaneously implanted into 6-week-old female BALB/c mice when the tumor size reached 50 mm3 mice (n = 10 animals/group) were treated for 3 consecutive as indicated in the Methods section. F. Percentage of CD4+/CD8+ intratumor T-lymphocytes (TILs) collected after tumor digestion and analyzed by flow cytometry, in duplicates. Data are means + SD. ***p < 0.001: treated group vs CTRL group; °°°p < 0.001: PT+MLN-treated cells vs PT-treated cells. G. Representative immunohistochemical imaging of CD4+ and CD8+ TILs. Scale bar: 100 μm. (10x ocular, 40x objective). At least 10 fields were examined for each conditionBack to article page